Laekna Inc 02105
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- HKD 5.95
- Day Range
- HKD 5.76–6.32
- 52-Week Range
- HKD 3.14–26.45
- Bid/Ask
- HKD 6.18 / HKD 6.19
- Market Cap
- HKD 2.41 Bil
- Volume/Avg
- 5.2 Mil / 6.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Laekna Inc is a science-driven, clinical-stage biotechnology company. The company has established a comprehensive R&D infrastructure to accelerate the development of molecules from discovery to registrational trials. It has initiated one clinical trial and another five clinical trials for its Core Products LAE002 and LAE001. Among these six clinical trials, three multi-regional clinical trials (MRCTs) are designed to address medical needs in the standard of care (SOC)-resistant cancers. Laekna has two Core Products and 14 other pipeline product candidates. Core Product LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 89
- Website
- https://www.laekna.com
Comparables
Valuation
|
Metric
|
02105
|
06978
|
09688
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.72 | 8.90 | 1.93 |
Price/Sales | — | — | 5.73 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
02105
|
06978
|
09688
|
|---|---|---|---|
Quick Ratio | 9.91 | 1.77 | 4.29 |
Current Ratio | 9.98 | 1.81 | 4.63 |
Interest Coverage | −447.63 | −39.58 | — |
Quick Ratio
02105
06978
09688
Profitability
|
Metric
|
02105
|
06978
|
09688
|
|---|---|---|---|
Return on Assets (Normalized) | −48.47% | −26.86% | −22.36% |
Return on Equity (Normalized) | — | −49.11% | −26.78% |
Return on Invested Capital (Normalized) | — | −33.40% | −30.45% |
Return on Assets
02105
06978
09688
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Cymrvyblg | Lbp | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mkctcxdmq | Knscw | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Tsdgcgz | Jpxtfq | $97.8 Bil | |
MRNA
| Moderna Inc | Bgdgtpbl | Rjbs | $41.3 Bil | |
ARGX
| argenx SE ADR | Bcnmgjcxc | Zkym | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Grwbvhfh | Bvjj | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Jsypfhd | Jtzvcv | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Zmqzmtl | Rwsylr | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Fkfxtxbbj | Psqtl | $12.5 Bil | |
INCY
| Incyte Corp | Lszzmytm | Pttxm | $11.6 Bil |